Garrett M Fitzmaurice
Overview
Explore the profile of Garrett M Fitzmaurice including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2978
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zanarini M, Temes C, Glass I, Frankenburg F, Fitzmaurice G, Unruh B, et al.
Am J Addict
. 2025 Feb;
PMID: 40001161
Background And Objectives: The purpose of this study is to detail the long-term course of substance use disorders (SUDs) among patients with borderline personality disorder (BPD) and subjects with other...
2.
Glass I, Frankenburg F, Fitzmaurice G, Zanarini M
J Pers Disord
. 2024 Dec;
38(6):503-519.
PMID: 39705102
This study describes the 8-year course of physical and psychosocial impairment in middle-aged patients with borderline personality disorder (BPD) and other personality disorders (OPD). This study also compares BPD subgroups...
3.
Hein K, Glass I, Frankenburg F, Fitzmaurice G, Zanarini M
J Affect Disord
. 2024 Nov;
372:234-240.
PMID: 39613044
Patients with borderline personality disorder (BPD) suffer from a variety of affective symptoms, including emptiness. Emptiness has received less attention, yet causes severe suffering and impairment. This study's primary aim...
4.
Zanarini M, Frankenburg F, Hein K, Glass I, Fitzmaurice G
J Clin Psychiatry
. 2024 Oct;
85(4).
PMID: 39480146
The first purpose of this study was to determine time to attainment of symptomatic remissions and recoveries of 2-12 years duration for those with borderline personality disorder (BPD) and patients...
5.
Agabio R, Lopez-Pelayo H, Bruguera P, Huang S, Sardo S, Pecina M, et al.
Pharmacol Res
. 2024 Oct;
209:107454.
PMID: 39396764
Baseline severity of alcohol use disorder (AUD) is an influencing factor in the response to medications recommended for the treatment of AUD. The scarce efficacy of AUD medications partly justifies...
6.
Glass I, Frankenburg F, Fitzmaurice G, Zanarini M
Personal Ment Health
. 2024 Sep;
18(4):414-423.
PMID: 39297409
This study describes the 6-year course of grit scores among patients with borderline personality disorder (BPD) who have and have not experienced a symptomatic and psychosocial recovery. This study also...
7.
McHugh R, McCarthy M, Bichon J, Nguyen M, Kneeland E, Ellis R, et al.
Psychol Addict Behav
. 2024 Sep;
38(8):819-826.
PMID: 39264682
Objective: Heightened reactivity to stress is associated with poor treatment outcome in people with substance use disorders (SUDs). Behavioral strategies can reduce stress reactivity; however, these strategies are understudied in...
8.
Zanarini M, Frankenburg F, Glass I, Fitzmaurice G
J Clin Psychiatry
. 2024 Aug;
85(3).
PMID: 39145674
Our first objective was to compare the prevalence of symptomatic disorders (formerly Axis I disorders) over 24 years of prospective follow-up among patients with borderline personality disorder (BPD) and other...
9.
McHugh R, Bailey A, Weiss R, Fitzmaurice G
Drug Alcohol Depend Rep
. 2024 Mar;
11:100226.
PMID: 38545409
Background: Although buprenorphine is an effective treatment for opioid use disorder (OUD), much remains to be understood about treatment non-response and methods for improving treatment retention. The addition of behavioral...
10.
McHugh R, Fitzmaurice G, Votaw V, Geyer R, Ragnini K, Greenfield S, et al.
J Subst Use Addict Treat
. 2024 Jan;
160:209296.
PMID: 38272120
Introduction: Anxiety disorders are highly prevalent among people with opioid use disorder (OUD), and they have a negative impact on disorder course and treatment outcomes. The objective of this Stage...